Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1

Cell Reports

Volumn 10, Issue 11, 2015, Pages 1850-1860

  Najjar, Malek ^a   Suebsuwong, Chalada ^b   Ray, SoumyaS ^d   Thapa, RoshanJ ^e   Maki, JennyL ^a   Nogusa, Shoko ^e   Shah, Saumil ^a   Saleh, Danish ^a   Gough, PeterJ ^f   Bertin, John ^f   Yuan, Junying ^g   Balachandran, Siddharth ^e   Cuny, GregoryD ^c   Degterev, Alexei ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Houston   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f GLAXOSMITHKLINE   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CS 4; CS 6; GSK 872; IMATINIB; NECROSTATIN 1; PN 10; PONATINIB; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; REBASTINIB; RECEPTOR INTERACTING PROTEIN KINASE 1; RECEPTOR INTERACTING PROTEIN KINASE 1 INHIBITOR; RECEPTOR INTERACTING PROTEIN KINASE 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK1 PROTEIN, HUMAN; RIPK3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; ENZYME SPECIFICITY; HEK293 CELL LINE; HUMAN; JURKAT CELL LINE; MOLECULAR DOCKING; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HEK293 CELLS; HUMANS; IMIDAZOLES; JURKAT CELLS; MICE; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIDAZINES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; SUBSTRATE SPECIFICITY;

EID: 84925690563     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.02.052     Document Type: Article

References (40)

1. Beard H., Cholleti A., Pearlman D., Sherman W., Loving K.A. Applying physics-based scoring to calculate free energies of binding for single amino acid mutations in protein-protein complexes. PLoS ONE 2013, 8:e82849.
2. Biton S., Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell 2011, 145:92-103.
3. Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., Chan F.K. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137:1112-1123.
4. Choi S., Keys H., Staples R.J., Yuan J., Degterev A., Cuny G.D. Optimization of tricyclic Nec-3 necroptosis inhibitors for invitro liver microsomal stability. Bioorg. Med. Chem. Lett. 2012, 22:5685-5688.
5. Christofferson D.E., Yuan J. Necroptosis as an alternative form of programmed cell death. Curr. Opin. Cell Biol. 2010, 22:263-268.
6. Christofferson D.E., Li Y., Hitomi J., Zhou W., Upperman C., Zhu H., Gerber S.A., Gygi S., Yuan J. A novel role for RIP1 kinase in mediating TNFα production. Cell Death Dis. 2012, 3:e320.
7. Cuda C.M., Misharin A.V., Gierut A.K., Saber R., Haines G.K., Hutcheson J., Hedrick S.M., Mohan C., Budinger G.S., Stehlik C., Perlman H. Caspase-8 acts as a molecular rheostat to limit RIPK1- and MyD88-mediated dendritic cell activation. J.Immunol. 2014, 192:5548-5560.
8. Dannappel M., Vlantis K., Kumari S., Polykratis A., Kim C., Wachsmuth L., Eftychi C., Lin J., Corona T., Hermance N., et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014, 513:90-94.
9. Degterev A., Huang Z., Boyce M., Li Y., Jagtap P., Mizushima N., Cuny G.D., Mitchison T.J., Moskowitz M.A., Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 2005, 1:112-119.
10. Degterev A., Hitomi J., Germscheid M., Ch'en I.L., Korkina O., Teng X., Abbott D., Cuny G.D., Yuan C., Wagner G., et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 2008, 4:313-321.
11. Dillon C.P., Weinlich R., Rodriguez D.A., Cripps J.G., Quarato G., Gurung P., Verbist K.C., Brewer T.L., Llambi F., Gong Y.N., et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 2014, 157:1189-1202.
12. Dondelinger Y., Aguileta M.A., Goossens V., Dubuisson C., Grootjans S., Dejardin E., Vandenabeele P., Bertrand M.J. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ. 2013, 20:1381-1392.
13. Duprez L., Takahashi N., Van Hauwermeiren F., Vandendriessche B., Goossens V., Vanden Berghe T., Declercq W., Libert C., Cauwels A., Vandenabeele P. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 2011, 35:908-918.
14. Elinav E., Nowarski R., Thaiss C.A., Hu B., Jin C., Flavell R.A. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 2013, 13:759-771.
15. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J.Med. Chem. 2004, 47:1739-1749.
16. Harris P.A., Bandyopadhyay D., Berger S.B., Campobasso N., Capriotti C.A., Cox J.A., Dare L., Finger J.N., Hoffman S.J., Kahler K.M., et al. Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Med. Chem. Lett. 2013, 4:1238-1243.
17. Hayes J.M., Skamnaki V.T., Archontis G., Lamprakis C., Sarrou J., Bischler N., Skaltsounis A.L., Zographos S.E., Oikonomakos N.G. Kinetics, insilico docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP-binding site inhibitors: the role of water molecules examined. Proteins 2011, 79:703-719.
18. He S., Liang Y., Shao F., Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc. Natl. Acad. Sci. USA 2011, 108:20054-20059.
19. Huron D.R., Gorre M.E., Kraker A.J., Sawyers C.L., Rosen N., Moasser M.M. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin. Cancer Res. 2003, 9:1267-1273.
20. Jagtap P.G., Degterev A., Choi S., Keys H., Yuan J., Cuny G.D. Structure-activity relationship study of tricyclic necroptosis inhibitors. J.Med. Chem. 2007, 50:1886-1895.
21. Kaiser W.J., Sridharan H., Huang C., Mandal P., Upton J.W., Gough P.J., Sehon C.A., Marquis R.W., Bertin J., Mocarski E.S. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J.Biol. Chem. 2013, 288:31268-31279.
22. Kaiser W.J., Daley-Bauer L.P., Thapa R.J., Mandal P., Berger S.B., Huang C., Sundararajan A., Guo H., Roback L., Speck S.H., et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc. Natl. Acad. Sci. USA 2014, 111:7753-7758.
23. Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M., Karplus M., Cole P.A., Kuriyan J. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol. 2006, 4:e144.
24. Linkermann A., Green D.R. Necroptosis. N.Engl. J. Med. 2014, 370:455-465.
25. Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2:358-364.
26. Lukens J.R., Vogel P., Johnson G.R., Kelliher M.A., Iwakura Y., Lamkanfi M., Kanneganti T.D. RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3. Nature 2013, 498:224-227.
27. Maki J.L., Degterev A. Activity assays for receptor-interacting protein kinase 1:a key regulator of necroptosis. Methods Mol. Biol. 2013, 1004:31-42.
28. Maki J.L., Tres Brazell J., Teng X., Cuny G.D., Degterev A. Expression and purification of active receptor interacting protein 1 kinase using a baculovirus system. Protein Expr. Purif. 2013, 89:156-161.
29. McNamara C.R., Ahuja R., Osafo-Addo A.D., Barrows D., Kettenbach A., Skidan I., Teng X., Cuny G.D., Gerber S., Degterev A. Akt Regulates TNFα synthesis downstream of RIP1 kinase activation during necroptosis. PLoS ONE 2013, 8:e56576.
30. Orozco S., Yatim N., Werner M.R., Tran H., Gunja S.Y., Tait S.W., Albert M.L., Green D.R., Oberst A. RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis. Cell Death Differ. 2014, 21:1511-1521.
31. Takahashi N., Duprez L., Grootjans S., Cauwels A., Nerinckx W., DuHadaway J.B., Goossens V., Roelandt R., Van Hauwermeiren F., Libert C., et al. Necrostatin-1 analogues: critical issues on the specificity, activity and invivo use in experimental disease models. Cell Death Dis. 2012, 3:e437.
32. Teng X., Degterev A., Jagtap P., Xing X., Choi S., Denu R., Yuan J., Cuny G.D. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:5039-5044.
33. Teng X., Keys H., Jeevanandam A., Porco J.A., Degterev A., Yuan J., Cuny G.D. Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:6836-6840.
34. Teng X., Keys H., Yuan J., Degterev A., Cuny G.D. Structure-activity relationship and liver microsome stability studies of pyrrole necroptosis inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:3219-3223.
35. Thapa R.J., Nogusa S., Chen P., Maki J.L., Lerro A., Andrake M., Rall G.F., Degterev A., Balachandran S. Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc. Natl. Acad. Sci. USA 2013, 110:E3109-E3118.
36. Upton J.W., Kaiser W.J., Mocarski E.S. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 2012, 11:290-297.
37. Vanlangenakker N., Vanden Berghe T., Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ. 2012, 19:75-86.
38. Xie T., Peng W., Liu Y., Yan C., Maki J., Degterev A., Yuan J., Shi Y. Structural basis of RIP1 inhibition by necrostatins. Structure 2013, 21:493-499.
39. Zhao Z., Wu H., Wang L., Liu Y., Knapp S., Liu Q., Gray N.S. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?. ACS Chem. Biol. 2014, 9:1230-1241.
40. Zhou T., Commodore L., Huang W.S., Wang Y., Thomas M., Keats J., Xu Q., Rivera V.M., Shakespeare W.C., Clackson T., et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem. Biol. Drug Des. 2011, 77:1-11.